A WEARABLE medical device that delivers electrical fields through the scalp helped to extend the survival of patients with lethal brain tumors, according to data presented Sunday.
In a study involving major medical centers in the United States and abroad, the novel treatment was used to administer alternating, low-intensity "tumor-treating fields" to newly diagnosed glioblastoma patients who also were getting chemotherapy. Such electrical fields may block the division of cancer cells and cause their demise, according to Roger Stupp, the study's lead investigator and a neuro-oncologist at the Northwestern University Feinberg School of Medicine.
Stupp, who has worked on the device for several years, acknowledged that it has prompted considerable skepticism from some experts in the field. Although the new data have not yet been peer-reviewed, he said he believes the results "firmly establish the survival benefit."
The study, presented at the annual meeting of the American Association for Cancer Research in Washington, D.C., involved 695 adult patients who were enrolled between July 2009 and November 2014. It found that the median survival for patients who were randomly assigned to use the device while getting the chemo drug temozolomide lived a median of 21 months compared with 16 months for those assigned to receive chemo without the device.
"I think this is fascinating, but the improvement is still quite modest," said George Demetri, an oncologist at the Dana-Farber Cancer Institute who was on the AACR committee that accepted and highlighted the abstract. Exploring non-drug therapies is important given that glioblastoma patients survive, on average, less than 15 months following their diagnosis. "I'm in favor of any incremental benefit" for such a lethal disease, Demetri said.
Some critics - and even some supporters - have said Stupp should have designed the trial so that one group of patients would have gotten a placebo in the form of a device without any electrical current. Doing so, they noted, would have ensured that the reported benefit was valid. Stupp counters that such a sham device would have been impractical since patients would have known the difference because of the warming sensation the actual treatment causes on the scalp.
Two prominent brain-cancer specialists declined to discuss the study, signaling that they remain dubious.
The technology, called Optune, is manufactured by Novocure Inc. Interim results for the first 315 patients enrolled in the study, which were published in 2015 in JAMA, prompted an independent data and safety monitoring committee to recommend that the trial be ended early so that all patients could get the device if they wanted. The latest data show that the two-year survival rate for the full group of patients was 43 percent for those using the device while getting temozolomide, compared with 31 percent for those only receiving chemo. The five-year rate was 13 percent vs. 5 percent.
Optune has several components. The device has a generator that can be plugged into an electrical outlet or powered by a battery. It produces an electrical field that is conveyed via wires to four adhesive patches taped in place on a patient's shaved scalp. Each patch has an array of nine electrode discs. The electrical field being delivered changes direction rapidly, which Stupp speculates disrupts the rapidly dividing cancer cells but does not affect healthy cells.
The device was initially approved by the Food and Drug Administration in 2011 to treat patients with glioblastoma that had returned after chemotherapy. In 2015, the agency approved the treatment for newly diagnosed patients who also were getting temozolomide, based on the interim data of the second trial. At the time, the FDA noted that the treatment wasn't a cure but seemed to increase survival by several months.
Researchers still aren't exactly sure how the device works. "It was a controversial approach," said Patrick Wen, director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute, who has not been involved in the trial. But he predicted that skepticism will begin to wane given the new "positive" data. Tumor-treating fields now are in early-stage testing for ovarian and pancreatic cancers.
Jessica Morris of Brooklyn was diagnosed with glioblastoma a year ago after having a seizure while hiking with friends. The 53-year-old public relations executive, who has gone through surgery, radiation, chemotherapy and immunotherapy, began using Optune in May. Its manufacturer recommends that it be worn at least 18 hours a day. Morris typically adds on several hours.
Morris said she replaces the patches and shaves her head a few times a week. Because those arrays "look a bit weird," she wears a scarf. She said she has had no effects other than feeling her head get a bit warm from the electrical fields. She hopes to extend her remission as long as possible and then look for an appropriate clinical trial.
Trial investigator Andrew Lassman, the chief of neuro-oncology at Columbia University, first heard about the device some years ago. He remembers thinking, "What is this thing, is it a joke?" Now he believes the approach is here to stay - "I don't think it's sci-fi," he said - and calls the results "pretty good" even though the improvements are "incremental, not curative."
He said that only 5 percent to 10 percent of his patients have opted to use the device. One reason is that it's impossible to hide: "For some patients, they'll say, 'I'm proud to display that I'm fighting this cancer.' But o thers say, 'I don't want anyone to know my business, I'd prefer to get an IV or a pill and be private.'"
At $21,000 a month, it's also costly. Standard Medicare doesn't cover it, and some other insurers are balking, as well. Novocure's vice president for financial and investor relations, Ashley Cordova, said the company has financial assistance programs in an effort to ensure that everyone prescribed the device can get it.
The Washington Post
Mon Apr 03 2017
Stupp, who has worked on the device for several years, acknowledged that it has prompted considerable skepticism from some experts in the field.
Thai resort island Phuket grapples with growing garbage crisis
By the end of year, the island could be producing up to 1,400 tonnes of trash a day, overwhelming its sole landfill, deputy mayor says.
Analysis - Biden to hand unfinished agenda to Trump for chaotic Mideast
Joe Biden's record on the world stage is likely to be heavily defined by his handling of the 15-month war in Gaza.
Biden administration will not enforce TikTok ban, says White House official
This leaves the incoming Donald Trump administration to make the decision, according to a White House official.
Hamas set to release first hostages under Gaza ceasefire deal, Israel says
If successful, the ceasefire would halt fighting that has razed much of heavily urbanised Gaza, killed over 46,000 people.
Pakistan's Imran Khan handed 14 years jail term in land graft case
Imran Khan's wife Bushra Bibi was also found guilty and sentenced to seven years in prison.
'It starts now': South Korea's President Yoon defiant as police closed in
Yoon Suk-Yeol remains in detention and is refusing to talk to investigators.
Japanese woman charged with concealing baby's birth
Noda Junko pleaded not guilty to a charge of concealing the birth of a baby girl by dumping the infant in a shopping mall toilet in Cheras.
ASEAN Sec-Gen attends 4th ADGMIN + U.S. meeting
ADGMIN the U.S. is a series of meetings between the ASEAN Digital Ministers' Meeting (ADGMIN) and the United States.
Najib admits relying on Jho Low's assistance despite doubts and discomfort
Najib reveals that on March 6, 2015, Tan Sri Tong Kooi Ong told him Jho Low was guilty of wrongdoing and should be investigated.
Malaysia, UK strengthen trade and investment ties in inaugural ministerial-led Joint Economic and Trade Committee meeting
The UK was Malaysia's 21st-largest trading partner from January to November 2024 and the fourth-largest trading partner in Europe.
448 children from GISB homes returned to their families - Nancy
Datuk Seri Nancy Shukri assures parents wishing to reclaim their children need not worry and encouraged them to approach the ministry.
TikTok's fight against going dark gains support from key US lawmakers
The prospect of a TikTok ban has already triggered some users to seek alternatives.
China's population falls for a third consecutive year
The National Bureau of Statistics says the total number of people in China dropped by 1.39 million to 1.408 billion in 2024.
Hardline Israeli minister Ben-Gvir threatens to quit over Gaza deal
Itamar Ben-Gvir says he would resign from Netanyahu's govt if it ratifies the ceasefire deal in Gaza, which he has strongly opposed.
US says Gaza ceasefire to start as planned despite 'loose end'
We're tying up that loose end as we speak, says Antony Blinken.
Meta's 'Community Notes' model will not apply to paid ads
Community Notes on Meta Platforms will be enabled for organic content, posts that Meta hasn't been paid to promote.
South Korea investigators to file request to extend President Yoon's detention
Investigators must request court approval for a detention warrant to hold Yoon Suk-Yeol in custody for up to 20 more days.
Israel set to approve Gaza ceasefire, hostage deal, Netanyahu's office says
The security cabinet would meet on Friday before a full meeting of the cabinet later to approve the deal, Netanyahu's office says.
Bird feathers, blood found in both engines of crashed jet in South Korea, source says
Two minutes before the pilot declared the Mayday emergency call, air traffic control had urged caution due to "bird activity" in the area.
TNB’s UK venture in RE to benefit Malaysia in tech transfer - PM
The Prime Minister emphasises that Malaysia is actively seeking new investments in the RE sector, driven by robust economic growth.